Fennec Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Fennec Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Fennec Pharmaceuticals Inc Strategy Report
- Understand Fennec Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Fennec Pharmaceuticals Inc (Fennec) formerly Adherex Technologies Inc, develops drugs for cancer treatments. The company lead product candidate, Pedmark, for the prevention of cisplatin-induced hearing loss and ototoxicity in children. The company has licensing agreements with Oregon Health & Science University for development of its drug candidates. The company seeks to establish relationships with contract research organizations, universities and other institutions for development of its drug candidates. Fennec is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
68 Tw Alexander Dr, Po Box 13628, Research Triangle Park, North Carolina, 27709
Website
fennecpharma.com
Telephone
1 919 6364530
No of Employees
36
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FRX (TSE)
Revenue (2022)
$21.3M
1284.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
32.3%
(2022 vs 2021)
Market Cap*
$247.5M
Net Profit Margin (2022)
XYZ
95.1%
(2022 vs 2021)
* As of and is in US$
Fennec Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| PEDMARK (STS): prevention of cisplatin induced hearing loss |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In January, the company received orphan drug exclusivity from U.S FDA for Pedmark. |
| 2022 | New Products/Services | In October, the company announced the commercial availability of Pedmark in the United States. |
| 2022 | Regulatory Approval | In September, the company announced that the U.S. Food and Drug Administration (FDA) approved PEDMARK (sodium thiosulfate injection) to reduce the risk of ototoxicity. |
Competitor Comparison
| Key Parameters | Fennec Pharmaceuticals Inc | Novartis AG | Merck KGaA | Taiho Pharmaceutical Co Ltd | Astrazeneca International |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Germany | Japan | United States of America |
| City | Research Triangle Park | Basel | Darmstadt | Tokyo | - |
| State/Province | North Carolina | - | Hessen | Tokyo | Puerto Rico |
| No. of Employees | 36 | 76,057 | 62,908 | 2,170 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Khalid Islam | Chairman | Executive Board | 2014 | 67 |
| Rostislav Raykov | Director; Chief Executive Officer | Executive Board | 2009 | 46 |
| Robert Andrade | Chief Financial Officer | Senior Management | 2015 | 47 |
| Ananya Bhattacharya | Head - Medical Affairs & Safety | Senior Management | - | - |
| Todd DeMarb | Vice President - Market Access and Commercial Supply | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer